Alpha Cognition launches ZUNVEYL for Alzheimer's treatment

Alpha Cognition Inc. has officially launched ZUNVEYL, a new treatment for mild to moderate Alzheimer's disease. This marks the first FDA-approved oral medication for Alzheimer's in the last ten years. The company aims to provide effective solutions for those affected by the disease. ZUNVEYL is designed to enhance cognitive function by improving cholinergic activity in the brain. It is available in three doses: 5 mg, 10 mg, and 15 mg. Patients can get ZUNVEYL through prescriptions filled at pharmacies across the country. To support this launch, Alpha Cognition has assembled a sales team with extensive experience in the pharmaceutical industry, particularly in long-term care markets. The team is focused on promoting ZUNVEYL to healthcare providers and ensuring quick access for patients. The launch of ZUNVEYL could address the needs of many individuals who have limited treatment options for Alzheimer’s disease. Alpha Cognition plans to actively engage with healthcare professionals, caregivers, and insurers to facilitate patient education and access. ZUNVEYL can cause side effects, including nausea, vomiting, and dizziness. The company advises patients to be closely monitored for any serious reactions, especially those with existing health issues. Patients are also encouraged to report any side effects to the FDA.